This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): E Keppra [Japan], levetiracetam immediate release, L059
Description: BioMedTracker has separate drug profiles for the IR and XR formulations of Keppra. Please also see Keppra XR.
All historical revenue for Keppra IR and Keppra XR is recorded under Keppra IR.
The precise mechanism(s) by which Keppra exerts its antiepileptic effect is unknown. Keppra binds to the SV2A synaptic vesicle protein. In an animal model, affinity for this protein has been correlated with anti-seizure activity, though its function has not definitively been established.
Deal Structure: In June 2008, UCB and Otsuka Pharmaceuticals announced that the companies signed collaboration agreements related to UCBs two products in Japan. UCB and Otsuka will co-promote Keppra for the adjunctive treatment of partial onset seizures and Cimzia for the treatment of Crohns Disease. UCB and Otsuka will also co-develop and co-promote Keppra and Cimzia in other indications. UCB and Otsuka have agreed on economic terms for Japan under which UCB receives up to 113 million upfront and milestone payments as well as funding for the clinical development of Keppra and Cimzia.
Partners: Otsuka Holdings Co., Ltd.
Keppra IR News
Pink Sheet Business and Financial News, In Brief
Additional information available to subscribers only: